LB-100

N/A

Report date: 2024/06/27 10:12:55
NME

Base Information

Drug NameLB-100
Drug Alias NameLB-100LB-1.0LB-1(Lixte)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein phosphatase 2A inhibitors
TargetsProtein phosphatase 2A
Therapy Area/IndicationsMyelodysplastic SyndromesSmall Cell Lung CarcinomaOvarian Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLixte Biotechnology Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncode Institute (Utrecht)The Netherlands Cancer InstituteNational Cancer Institute +[6] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesSmall Cell Lung CarcinomaOvarian Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A